Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 61 - 70 of 92

Insights

Inhalation drug products have a multitude of benefits when delivering treatment to the lungs, including a faster onset because of direct delivery to the area requiring therapeutic treatment and reduced occurrence of adverse effects.

Insights

Staffan Widengren, Director of Corporate Projects at Recipharm recently took part in a Manufacturing Chemist roundtable to discuss the challenge of new serialisation regulations put in place to protect against counterfeit medicines.

Insights

This month Erik Haeffler, Vice President of Manufacturing Services at Recipharm took to the Medicine Maker alongside other serialisation experts to discuss whether the industry is ready for the upcoming regulatory deadlines and to dispel the misconception that serialisation is simply ‘adding a label to the box.’

Insights

The approach involved testing the interactions of 30 different excipients with six commercially available drugs, with a diverse range of properties.

Dr Amjad Alhalaweh, a formulation scientist at Recipharm, takes to Pharmaceutical Manufacturing 

Insights

Erik Haeffler, Vice President of Manufacturing Services and Head of CSR at Recipharm, discusses the DSCSA enforcement delay with Contract Pharma and outlines what companies should be doing now to ensure they are ready ahead of the deadline next year.

Insights

Despite the FDA’s decision to delay the active enforcement of the Drug Supply Chain Security Act (DSCSA) in the US until 2018, companies need to continue to press ahead with their preparations for serialisation. 

Insights

Recipharm’s Torkel Gren joins Synthonics and Rush University representatives to discuss a new technology that improves pharmacokinetic (PK) properties in metal coordinated pharmaceuticals (MCPs).

Insights

Contract Pharma held a roundtable with industry experts from across the contract development and manufacturing space to explore current and future outsourcing relationships within the pharmaceutical industry.

Insights

The US Food and Drug Administration (FDA) has made the decision to delay the active enforcement of the Drug Supply Chain Security Act (DSCSA), aimed at combatting the issue of counterfeit medicines entering the supply chain.

Insights

With the deadline for new regulations on serialisation looming closer for both the US and European markets, the biggest challenge many pharmaceutical companies face is time.